Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
$63.17
-1.0%
$65.74
$58.97
$73.28
$543.49M0.6370,555 shs9,558 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$151.69
-1.0%
$155.67
$140.68
$169.99
$365.06B0.427.95 million shs888,171 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$76.89
-0.1%
$82.44
$73.31
$134.63
$193.06B0.4316.10 million shs1.79 million shs
Novartis AG stock logo
NVS
Novartis
$111.91
-0.8%
$109.86
$96.06
$120.92
$236.49B0.61.58 million shs299,095 shs
Pfizer Inc. stock logo
PFE
Pfizer
$22.88
-0.7%
$23.50
$20.92
$31.54
$129.83B0.5840.96 million shs8.43 million shs
PJP
Invesco Pharmaceuticals ETF
$78.87
-0.7%
$80.45
$72.25
$89.87
$233.45M0.518,533 shs1,368 shs
XPH
SPDR S&P Pharmaceuticals ETF
$39.50
-0.8%
$40.36
$35.22
$48.76
$136.31M0.6148,199 shs2,739 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
-2.06%+2.77%-0.34%-10.32%-3.90%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.27%+4.63%-2.44%-4.04%+1.27%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-1.32%+4.67%-1.31%-12.27%-41.21%
Novartis AG stock logo
NVS
Novartis
+0.44%+7.24%+2.00%+5.17%+9.68%
Pfizer Inc. stock logo
PFE
Pfizer
-1.92%+4.77%+4.48%-10.81%-19.26%
PJP
Invesco Pharmaceuticals ETF
-2.07%+2.14%+3.32%-8.60%-1.61%
XPH
SPDR S&P Pharmaceuticals ETF
-2.69%+2.13%+4.65%-11.42%-3.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.9538 of 5 stars
3.35.04.23.93.42.51.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9985 of 5 stars
3.35.05.03.94.02.53.8
Novartis AG stock logo
NVS
Novartis
1.3731 of 5 stars
1.03.02.50.02.40.01.9
Pfizer Inc. stock logo
PFE
Pfizer
4.9955 of 5 stars
4.33.04.24.33.81.73.1
PJP
Invesco Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
2.66
Moderate Buy$63.510.54% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.55
Moderate Buy$170.8812.65% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.50
Moderate Buy$109.1942.01% Upside
Novartis AG stock logo
NVS
Novartis
2.00
Hold$123.3810.24% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1727.50% Upside
PJP
Invesco Pharmaceuticals ETF
2.69
Moderate Buy$78.87N/A
XPH
SPDR S&P Pharmaceuticals ETF
2.70
Moderate Buy$39.510.04% Upside

Current Analyst Ratings Breakdown

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Cautious
5/14/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$115.00 ➝ $84.00
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$169.00 ➝ $153.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/24/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$85.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/17/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/17/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
(Data available from 5/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.09$12.46 per share12.17$29.69 per share5.11
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$63.92B3.02$2.67 per share28.82$14.85 per share5.18
Novartis AG stock logo
NVS
Novartis
$53.22B4.44$11.16 per share10.03$21.59 per share5.18
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.08$3.59 per share6.38$15.81 per share1.45
PJP
Invesco Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
N/AN/A23.46N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9922.8113.702.5618.20%34.24%13.63%7/16/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8711.427.770.7726.67%45.35%17.36%7/29/2025 (Estimated)
Novartis AG stock logo
NVS
Novartis
$11.94B$6.4019.0412.701.7023.56%37.24%15.85%7/17/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3816.207.550.6412.62%19.47%8.09%7/29/2025 (Estimated)
PJP
Invesco Pharmaceuticals ETF
N/AN/A20.79N/AN/AN/AN/AN/A
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/A14.61N/AN/AN/AN/AN/A

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2025Q1 2025
Novartis AG stock logo
NVS
Novartis
$2.12$2.28+$0.16$1.83$12.92 billion$13.23 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
$1.161.84%N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.43%+5.43%57.84%64 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.21%+5.73%47.16%14 Years
Novartis AG stock logo
NVS
Novartis
$2.592.31%+5.34%40.47%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.52%+2.50%124.64%16 Years
PJP
Invesco Pharmaceuticals ETF
$0.911.15%N/AN/AN/A
XPH
SPDR S&P Pharmaceuticals ETF
$0.661.67%N/AN/AN/A

Latest PFE, MRK, JNJ, NVS, PJP, IHE, and XPH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.79
1.36
1.15
Novartis AG stock logo
NVS
Novartis
0.48
1.04
0.84
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
PJP
Invesco Pharmaceuticals ETF
N/AN/AN/A
XPH
SPDR S&P Pharmaceuticals ETF
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
iShares U.S. Pharmaceuticals ETF stock logo
IHE
iShares U.S. Pharmaceuticals ETF
N/A8.60 millionN/ANot Optionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
69,0002.51 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
101,7002.11 billion2.04 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.69 billion5.66 billionOptionable
PJP
Invesco Pharmaceuticals ETF
N/A2.96 millionN/ANot Optionable
XPH
SPDR S&P Pharmaceuticals ETF
N/A3.45 millionN/ANot Optionable

Recent News About These Companies

Capture European Growth with This Banking-Focused ETF
SPDR® S&P Regional Banking ETF
Pharma ETFs in Focus Post Solid Q2 Earnings
SPDR S&P Pharmaceuticals ETF (XPH)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
iShares U.S. Pharmaceuticals ETF stock logo

iShares U.S. Pharmaceuticals ETF NYSEARCA:IHE

$63.17 -0.61 (-0.96%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund's investment advisor is BlackRock Fund Advisors.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$151.69 -1.49 (-0.97%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$76.89 -0.10 (-0.12%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$111.91 -0.87 (-0.77%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Pfizer stock logo

Pfizer NYSE:PFE

$22.88 -0.17 (-0.72%)
As of 10:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Invesco Pharmaceuticals ETF NYSEARCA:PJP

$78.87 -0.53 (-0.67%)
As of 10:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The Fund normally invests at least 90% of its total assets in common stocks that consists of the Index. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.

SPDR S&P Pharmaceuticals ETF NYSEARCA:XPH

$39.50 -0.30 (-0.76%)
As of 10:54 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.